Recent SNTI News
- Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase • GlobeNewswire Inc. • 05/14/2026 12:45:00 PM
- Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program • GlobeNewswire Inc. • 05/14/2026 12:40:00 PM
- Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/13/2026 01:00:00 PM
- Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies • GlobeNewswire Inc. • 04/01/2026 12:45:00 PM
- Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update • GlobeNewswire Inc. • 03/27/2026 12:00:00 PM
- Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference • GlobeNewswire Inc. • 03/23/2026 01:00:00 PM
- Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference • GlobeNewswire Inc. • 03/03/2026 02:05:00 PM
- Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference • GlobeNewswire Inc. • 02/24/2026 02:15:00 PM
- Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development • GlobeNewswire Inc. • 02/20/2026 01:50:00 PM
- Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) • GlobeNewswire Inc. • 02/11/2026 01:35:00 PM
- Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 • GlobeNewswire Inc. • 02/03/2026 02:00:00 PM
- Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation • GlobeNewswire Inc. • 01/14/2026 02:15:00 PM
- Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference • GlobeNewswire Inc. • 01/09/2026 01:55:00 PM
- Senti Biosciences Announces New Employment Inducement Grants • GlobeNewswire Inc. • 12/18/2025 10:30:00 PM
- Senti Biosciences Shares Jump 29% After Strong Trial Results and FDA RMAT Status • IH Market News • 12/09/2025 02:54:49 PM
- Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia • GlobeNewswire Inc. • 12/09/2025 12:00:00 PM
- Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile • GlobeNewswire Inc. • 12/09/2025 12:00:00 PM
- Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET • GlobeNewswire Inc. • 12/04/2025 01:45:00 PM
- Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December • GlobeNewswire Inc. • 11/13/2025 09:30:00 PM
- Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 • GlobeNewswire Inc. • 11/03/2025 02:05:00 PM
- Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference • GlobeNewswire Inc. • 10/16/2025 01:05:00 PM
- Senti Bio to Present at BioJapan • GlobeNewswire Inc. • 10/06/2025 01:05:00 PM
- Senti Bio to Present at the MedInvest Biotech & Pharma Conference • GlobeNewswire Inc. • 09/18/2025 01:15:00 PM
- Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/02/2025 01:05:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/02/2025 12:15:16 PM
